Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)

v3.7.0.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)
3 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Condensed Consolidated Statements Of Operations    
Revenues, net $ 134,227 $ 230,413
Operating expenses:    
Cost of implants and other costs 23,350 40,453
Research and development 8,231
Selling, general and administrative 506,600 391,239
Termination of licensing agreement 132,804
Depreciation and amortization 8,389 573
Total operating expenses 546,570 565,069
Loss from operations (412,343) (334,656)
Other income (expenses):    
Net gain on settlement agreement
Interest expense, net (9,761,505) (165,232)
Loss on change in fair value of derivative liability (28,161,673) (28,697)
Total other income (expenses) (37,923,178) (193,929)
Loss before income taxes (38,335,521) (528,585)
Net loss $ (38,335,521) $ (528,585)
Net loss per common share, basic and diluted $ (0.19) $ (0.00)
Weighted average number of common shares outstanding, basic and diluted 202,611,873 164,938,457